News | May 12, 2026
JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
The appointment is effective from May 01, 2023 for five years
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Subscribe To Our Newsletter & Stay Updated
